Cognition Therapeutics provided recap of virtual KOL event

Cognition Therapeutics provided a recap of the virtual KOL event hosted on April 12, 2024. “The KOL roundtable we conducted featured a panel of Alzheimer’s disease expert clinicians and researchers who highlighted the need to find Alzheimer’s disease treatments that are less burdensome for patients and their care partners,” said Lisa Ricciardi, Cognition’s president and CEO. “They reinforced the importance of removing toxic oligomers as an important step in slowing the progress of Alzheimer’s disease and highlighted the need for new treatment modalities to use alone or in conjunction with the currently approved treatments.” The KOLs shared their perspectives on the currently approved immunotherapies for early Alzheimer’s disease, including perception of their effectiveness in targeting plaque, impact of amyloid related imaging abnormalities on commercial uptake, and the clinical meaningfulness of the reported changes in disease progression.